Please contact us: +49 (0)251 978240-0

Update Factory & Coffee Break Events

Stay up to date from a clinical and regulatory perspective in the Medtech sector

Our Update Factories & Coffee Break Events offer concise learning content on current regulatory topics. They help you understand changes and their impact on your organization early on and enable you to develop appropriate next steps.

What could the proposed changes under MDR 2.0 mean for clinical evaluation?

What we’ll be covering:

  • The key proposed MDR 2.0 changes and their potential impact on Clinical Evaluation

  • Potential changes to clinical evidence requirements and manufacturers’ ongoing obligations

  • The Notified Body perspective: How the proposed changes may be interpreted and implemented from a conformity assessment perspective, with insights from Richard Holborrow

  • Practical considerations for medical device manufacturers and clinical evaluation professionals to prepare for potential changes

already over

Article 61 (10) Team NB - Positioning Paper

What we’ll be covering:

  • What a well-founded justification under Article 61(10) must include—and what the Notified Body typically looks for
  • Common deficiencies seen in submissions, and practical ways to avoid them (before they become findings)
already over

MDR Delegated Act WET List

With the updated delegated act on the MDR, the WET list for Class III and implantable devices has been expanded—but not every addition has led to greater clarity.

What we’ll be covering:

Manufacturers are now faced with key questions:

  • Which products have actually been newly added?
  • To what extent should key terms be interpreted in practice?
  • Where does a reasonable interpretation end—and where does regulatory risk begin?